Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.44 |
| ▸ | GSK3A | P49840 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.41 |
| ▸ | PDGFRB | P09619 | 5/20 | 0.41 |
| ▸ | KDR | P35968 | 5/20 | 0.41 |
| ▸ | ALPL | P05186 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.34 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.34 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30963226 | 1.00 | DGAT1 (0.44) | DGAT1GSK3AGSK3BPDGFRBKDR | |
| SCHEMBL16077123 | 0.91 | DGAT1 (0.40) | DGAT1GSK3AGSK3BPDGFRBKDR | |
| SCHEMBL21198942 | 0.86 | GSK3A (0.42) | DGAT1GSK3AGSK3BPDGFRBKDR | |
| SCHEMBL29604376 | 0.86 | GSK3A (0.42) | DGAT1GSK3AGSK3BPDGFRBKDR | |
| SCHEMBL19806132 | 0.86 | DGAT1 (0.44) | DGAT1GSK3AGSK3BPDGFRBKDR | |
| SCHEMBL29858041 | 0.85 | PDGFRB (0.50) | DGAT1GSK3AGSK3BPDGFRBKDR | |
| SCHEMBL29604061 | 0.85 | ALPL (0.46) | DGAT1GSK3AGSK3BPDGFRBKDR | |
| SCHEMBL21199260 | 0.85 | DGAT1 (0.44) | DGAT1GSK3AGSK3BPDGFRBKDR | |
| SCHEMBL789862 | 0.85 | ALPL (0.46) | DGAT1GSK3AGSK3BPDGFRBKDR | |
| SCHEMBL26660219 | 0.85 | DGAT1 (0.44) | DGAT1GSK3AGSK3BPDGFRBKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11229638-B2 | Therapeutic heterocyclic compounds | GILEAD SCIENCES, INC. (US) | 2022-01-25 | — | — | US | disclosed |
| US-20200316035-A1 | THERAPEUTIC HETEROCYCLIC COMPOUNDS | GILEAD SCIENCES, INC. | 2020-10-08 | — | — | US | disclosed |
| US-9738653-B2 | Fused furans for the treatment of hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-08-22 | — | — | US | disclosed |
| US-20160024103-A1 | FUSED FURANS FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY | 2016-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11229638-B2 | Therapeutic heterocyclic compounds | SDHA, CYP11B2, ABCB1 | DGAT1 3302/4885GSK3A 3673/4885GSK3B 3385/4885 |
| US-20200316035-A1 | THERAPEUTIC HETEROCYCLIC COMPOUNDS | SDHA, CYP11B2, ABCB1 | DGAT1 3302/4885GSK3A 3673/4885GSK3B 3385/4885 |
| US-20160024103-A1 | FUSED FURANS FOR THE TREATMENT OF HEPATITIS C | HAVCR2, HCCS, GOT1 | DGAT1 1589/4885GSK3A 3809/4885GSK3B 3841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.